Comparison · NCT00090259-sae
Losartan 50 mg vs Losartan 150 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Losartan 50 mg vs Losartan 150 mg: serious adverse events. Trial comparisons, record NCT00090259-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00090259-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.361 | 0.34 | 0.383 | wilson | |
| Risk in group 2 | 0.37 | 0.348 | 0.391 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00839 | -0.0388 | 0.0221 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.977 | 0.899 | 1.06 | log | |
| Odds ratio, group 1 over group 2 | 0.964 | 0.846 | 1.1 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Losartan 50 mg than on Losartan 150 mg | 119 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Losartan 50 mg | 691 | 1,913 | EG000 | |
| Group 2 | Losartan 150 mg | 710 | 1,921 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
All adverse experiences that occurred during or up to 14 days after permanent or temporary discontinuation of the study treatment were included in the safety analyses. Per guidelines, endpoints were not reported as serious adverse experiences.
Source ClinicalTrials.gov
Trial
- Title
- Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)
- NCT number
- NCT00090259
- Phases
- PHASE3
- Conditions
- Heart Failure
- Interventions
- Losartan 50 mg, Losartan 150 mg
- Lead sponsor
- Organon and Co
- Results first posted
- 2010-08-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00090259?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00090259-sae